Hangzhou Biotest Biotech Co.,Ltd.

Equities

688767

CNE1000050H0

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 23/05/2024 am IST			5-day change	1st Jan Change
28.97 ^CNY	-1.16%		+0.59%	-4.29%

26/04	Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
23/02	Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tranche Update on Hangzhou Biotest Biotech Co.,Ltd.'s Equity Buyback Plan announced on November 6, 2023.

January 03, 2024

From November 3, 2023 to December 31, 2023, the company has repurchased 450,000 shares, representing 0.42% for CNY 14.76 million. With this, the company has completed the repurchase of 450,000 shares, representing 0.42% for CNY 14.76 million under the buyback announced on November 6, 2023.

Latest news about Hangzhou Biotest Biotech Co.,Ltd.

Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	27/04	CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02	CI
Tranche Update on Hangzhou Biotest Biotech Co.,Ltd.'s Equity Buyback Plan announced on November 6, 2023.	03/01	CI
Hangzhou Biotest Biotech Co.,Ltd.(XSSC:688767) dropped from S&P Global BMI Index	18/12	CI
Biotest Biotech to Repurchase Up to 100 Million Yuan Shares	06/11	MT
Hangzhou Biotest Biotech Co.,Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	06/11	CI
Hangzhou Biotest Biotech Co.,Ltd. authorizes a Buyback Plan.	03/11	CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/23/27	CI
Hangzhou Biotest Biotech Co.,Ltd.(XSSC:688767) added to S&P Global BMI Index	18/23/18	CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29	CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	28/23/28	CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	27/23/27	CI
Hangzhou Biotest’s COVID-19 Antigen Home Test Kit Cleared by US FDA for Emergency Use	26/22/26	MT
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	28/22/28	CI
Hangzhou Biotest Biotech Co.,Ltd.(SHSE:688767) added to Shanghai Stock Exchange Composite Index	08/22/08	CI
Hangzhou Biotest Biotech Co.,Ltd.(SHSE:688767) added to Shanghai Stock Exchange A Share Index	08/22/08	CI
Certain A Shares of Hangzhou Biotest Biotech Co.,Ltd. are subject to a Lock-Up Agreement Ending on 8-SEP-2022.	08/22/08	CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	25/22/25	CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	27/22/27	CI
Hangzhou Biotest Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	25/22/25	CI
Australia regulator to review price hike in COVID-19 antigen tests	04/22/04	RE

Chart Hangzhou Biotest Biotech Co.,Ltd.

Duration

Period

More charts

Company Profile

Hangzhou Biotest Biotech Co Ltd is a company mainly engaged in the research and development (R&D), production and sales of point-of-care testing (POCT) diagnostic reagents. The Company's products include reproductive health testing series, such as human chorionic gonadotropin testing reagent and luteinizing hormone testing reagent, and drug abuse testing series, such as morphine testing reagent and cocaine testing reagent, and infectious disease testing series, such as adenovirus testing reagent and typhoid antibody testing reagent, and tumor marker testing series, such as alpha fetoprotein detection reagent, and myocardial marker detection series, such as dimer detection reagent and myocardial series detection reagent.

Sector

Medical Equipment, Supplies & Distribution

Calendar

28/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
HANGZHOU BIOTEST BIOTECH CO.,LTD.	-4.29%	42Cr
BIOMÉRIEUX	-5.86%	1.21TCr
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-4.87%	807.09Cr
DIASORIN S.P.A.	+5.47%	567.16Cr
LANTHEUS HOLDINGS, INC.	+27.42%	547.57Cr
AUTOBIO DIAGNOSTICS CO., LTD.	-9.89%	411.78Cr
10X GENOMICS, INC.	-58.99%	274.73Cr
ANDON HEALTH CO., LTD.	+8.97%	261.68Cr
VITROLIFE AB	-5.19%	232.76Cr
MYRIAD GENETICS, INC.	+21.58%	210.61Cr

Diagnostic & Testing Substances